ARRIVENT BIOPHARMA INC (AVBP:NASDAQ)
$16.73 0.02 (0.1197%)
Analysed ARRIVENT BIOPHARMA INC (AVBP:NASDAQ) News Sources
ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers
07-05-2026
yahoo.com
ArriVent BioPharma Reports First Quarter 2026 Financial Results
11-05-2026
yahoo.com
A Look At ArriVent BioPharma (AVBP) Valuation After FDA Clears ARR-002 Oncology Candidate
10-05-2026
yahoo.com
ArriVent BioPharma Reports Second Quarter 2026 Financial Results
12-08-2026
yahoo.com
ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC
06-10-2026
yahoo.com
Why This Biotech Stock Is Having Its Worst Day Ever
06-10-2026
yahoo.com
ArriVent collapses on disappointing lung cancer data
06-10-2026
biopharmadive.com
AVBP Stock Crashes More Than 48% To All-Time Low After Lung Cancer Trial Setback – Retail Calls It ‘Way Undervalued’
06-10-2026
stocktwits.com
ArriVent’s stock plummets on Phase III NSCLC trial failure
07-10-2026
clinicaltrialsarena.com
Shanghai Allist shares slide after U.S. partner’s lung cancer drug trial fails
08-10-2026
yahoo.com
What is the current price of ARRIVENT BIOPHARMA INC (AVBP:NASDAQ)?
The current price of ARRIVENT BIOPHARMA INC (AVBP:NASDAQ) is $16.73.
ARRIVENT BIOPHARMA INC (AVBP:NASDAQ) absolute price change since previous trading day?
The absolute price change of ARRIVENT BIOPHARMA INC (AVBP:NASDAQ) since the previous trading day is $0.02.
ARRIVENT BIOPHARMA INC (AVBP:NASDAQ) percentage price change since previous trading day?
The percentage price change of ARRIVENT BIOPHARMA INC (AVBP:NASDAQ) since the previous trading day is 0.1197%.
What is the most recent average sentiment score for ARRIVENT BIOPHARMA INC (AVBP:NASDAQ)?
The most recent average sentiment score for ARRIVENT BIOPHARMA INC (AVBP:NASDAQ) is 50 out of 100.
What is the most recent average sentiment for ARRIVENT BIOPHARMA INC (AVBP:NASDAQ)?
The most recent sentiment for ARRIVENT BIOPHARMA INC (AVBP:NASDAQ) is .
SEC-8K** Filing Available For ARRIVENT BIOPHARMA INC (AVBP:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.